NDA 204768 · Genus
Tivorbex
Indomethacin · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 28, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Feb 24, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
557
100 Phase 3, 44 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 24, 2014 Original approval · Type 3 - New Dosage Form Summary ReviewLetterLabel
2 products under this application
- TIVORBEX · INDOMETHACIN 40MG · CAPSULE, ORAL · Discontinued
- TIVORBEX · INDOMETHACIN 20MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Indomethacin" as an intervention, any sponsor and status, largest first.
- Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP PancreatitisPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT05252754 · 4,874 participants (planned) · Start Jan 18, 2023 · Primary completion Dec 2026
Drug: Tacrolimus capsule; Placebo and 1 more · For: Post-ERCP Acute Pancreatitis
Sites: Baltimore, Maryland; Hyderabad, India; Kolkata, India · 5 sites in all
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal IndomethacinPivotal-lookingTerminated
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT03057769 · 3,300 participants · Start Feb 1, 2017 · Primary completion Oct 26, 2017
Drug: Papillary epinephrine spraying; Papillary saline spraying and 1 more · For: Pancreatitis; Endoscopic Retrograde Cholangiopancreatography
Sites: Xiamen, China; Lanzhou, China; Ankang, China · 10 sites in all
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- Oral Resveratrol to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02947932 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Mar 2018
Drug: Resveratrol; Indomethacin · For: Pancreatitis, Acute; Gastrointestinal Disease
- COX-2 Inhibitor to Prevent Post-ERCP PancreatitisPivotal-lookingStatus unknown
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
NCT02964403 · 2,700 participants (planned) · Start Dec 2016 · Primary completion Feb 2018
Drug: Cox-2; Indomethacin · For: Pancreatitis, Acute
- Rectal Indomethacin to Prevent Post-ERCP PancreatitisPivotal-lookingCompleted
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT02002650 · 2,600 participants · Start Dec 2013 · Primary completion Nov 2015
Drug: Pre-ERCP rectal Indomethacin; Post-operational Rectal Indomethacin · For: Post-ERCP Acute Pancreatitis
Sites: Lanzhou, China; Yinchuan, China; Xi'an, China · 6 sites in all
- Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP PancreatitisPivotal-lookingRecruiting
Chinese University of Hong KongAcademic, hospital or other
NCT03713879 · 1,734 participants (planned) · Start Mar 21, 2019 · Primary completion May 31, 2028
Drug: Indomethacin · For: Post ERCP Pancreatitis
Sites: Xi'an, China; Shanghai, China; Tianjin, China · 7 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
Elmunzer BJ, Foster LD, Serrano J, et al. · Lancet 2024 · Randomized Controlled Trial, Equivalence Trial
- Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis.
Mitra S, Florez ID, Tamayo ME, et al. · JAMA 2018 · Comparative Study, Systematic Review
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants.
Ohlsson A, Walia R, Shah SS · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Rectal diclofenac versus indomethacin for prevention of post-ERCP pancreatitis (DIPPP): a multicentre, double-blind, randomised, controlled trial.
Kang X, Xia M, Wang J, et al. · Gut 2025 · Multicenter Study, Randomized Controlled Trial
- Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia.
Fraser RC, Davis RH, Walker FS · J R Coll Gen Pract 1987 · Clinical Trial, Comparative Study
- An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients.
Ravichandran R, Mohan SK, Sukumaran SK, et al. · Sci Rep 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Genus
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.